August 11, 2005 |
Two former Bayer executives were indicted on charges that they participated in a global conspiracy to fix the price of chemicals used to improve the strength of tires, outdoor furniture, hoses and rubber belts. Jurgen Ick, former head of Bayer's Rubber Business Group, and Gunter Monn, the group's former marketing head, were named in the indictment, returned by a federal grand jury in San Francisco, the U.S. Justice Department said.
May 17, 2005 |
Former Bayer executive Wolfgang Koch has agreed to plead guilty to colluding in a price-fixing scheme that drove up the cost of rubber chemicals used to make tires, outdoor furniture and shoes in the U.S. during a three-year period, the Department of Justice said Monday. The plea agreement marks the latest development in a long-running antitrust investigation into an international price-rigging ring formed by some of the world's biggest rubber chemical manufacturers.
November 24, 2004 |
Say auf wiedersehen to Landon Donovan. The United States' most successful and highest-profile soccer player is heading back to Germany to fulfill the promise of his youth. Donovan, 22, announced Tuesday that he would leave the San Jose Earthquakes, which he led to Major League Soccer championships in 2001 and 2003, and rejoin Bayer Leverkusen of the German Bundesliga. Given Donovan's previous unhappy experience in Germany, it was not a decision made without misgivings, but he made it anyway.
November 23, 2004 |
Another pharmaceutical company may have concealed safety information about a dangerous drug -- this time Bayer and its once-popular cholesterol medication Baycol -- according to a report in a prominent medical journal. Baycol was pulled from the market in 2001, but an analysis released Monday by the Journal of the American Medical Assn. argued there were strong indications of its dangers three months after its introduction in 1998.
October 1, 2004 |
Bayer's U.S. unit agreed to plead guilty and pay a $33-million fine for conspiring to fix prices of a chemical used to make plastic grocery bags and other consumer products. The guilty plea by Bayer Corp. would be the first in a U.S. government investigation into price fixing for the chemical additive used in a variety of products, the Justice Department said. From Bloomberg News * PalmOne Inc.
September 14, 2004 |
Struggling pharmaceuticals company Schering-Plough Corp. and German chemical and drug maker Bayer have formed an alliance under which Schering-Plough will take over U.S. marketing of Bayer's primary care medicines. The partnership, announced Monday, could give Bayer a bigger presence in the world's biggest drug market while offering Schering-Plough badly needed new products to sell and a potentially key marketing partner for some of its drugs in Europe and Japan.
July 20, 2004 |
Bayer, the maker of Alka-Seltzer stomach remedies and inventor of aspirin, agreed to buy Roche Holding's nonprescription healthcare unit for $3 billion as its main drug business lags behind competitors such as Pfizer Inc. and Novartis. The expanded division would have about 5% of the over-the-counter drug market, Leverkusen, Germany-based Bayer said Monday. Germany's No. 2 drug and chemical maker also would gain full control of the U.S.
April 9, 2004 |
The Defense Department issued Bayer a subpoena demanding documents related to the German drug company's withdrawn cholesterol drug Baycol, the company said Thursday. Bayer voluntarily recalled Baycol, now linked to more than 100 deaths related to a fatal severe muscle condition called rhabdomyolysis, in August 2001.
December 2, 2003 |
Bayer, Germany's second-biggest drug and chemical maker, said it filed counterclaims in an arbitration demanding tens of millions of dollars in damages from Gen-Probe Inc. Bayer's counterclaims allege that Gen-Probe violated terms of a contract to develop clinical tests and instruments, the Leverkusen, Germany-based company said. Bayer doesn't expect the arbitration to be finished until late 2004.
August 28, 2003 |
Baxter International Inc., the world's largest maker of blood disease treatments, settled a lawsuit accusing Bayer Corp. and a former employee of stealing trade secrets about Baxter's products. Terms of the agreement weren't disclosed. Baxter had claimed that Gopal Dasari, a former Baxter Healthcare Corp. scientist who joined Bayer in May, had copied files on Baxter's products for hemophilia, cancer and kidney disease.